How to develop your own CNS drug
The development of novel drugs for neurodegenerative disorders has proven to be so difficult that many big Pharma companies have given up on it. Instead, they now rely on individual initiatives from researchers who are willing to take their own idea into development, with big pharma simply waiting for new leads to become sufficiently promising before acting on them. Much more than before, therefore, initiating the development of new CNS drugs has also become a responsibility of neuroscientist at universities and research institutes.
In this talk, and based on my own experiences in this context, I aim to explain how to commercially protect an idea for a new drug, how to turn such an idea into a business proposition, and how to get the money and support you need to start developing a new CNS drug. Finally, I will give a summary of the process of drug development itself, including the regulatory requirements that apply to this process.